{
    "organizations": [],
    "uuid": "c278ad61f2b26fa601e0b1a36385c6852d7c233e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-can-fite-reports-on-the-progress-o/brief-can-fite-reports-on-the-progress-of-its-phase-ii-nash-study-with-drug-candidate-namodenoson-idUSFWN1QI16N",
    "ord_in_thread": 0,
    "title": "BRIEF-Can Fite Reports On The Progress Of Its Phase II NASH Study With Drug Candidate Namodenoson",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Can Fite Biopharma Ltd:\n* CAN FITE REPORTS ON THE PROGRESS OF ITS PHASE II NASH STUDY WITH DRUG CANDIDATE NAMODENOSON\n* CAN FITE BIOPHARMA - ‍ANTICIPATES COMPLETION OF PATIENT ENROLLMENT TOWARD END OF 2018 AND DATA RELEASE IN FIRST HALF OF 2019 FROM PHASE II NASH STUDY​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T22:36:00.000+02:00",
    "crawled": "2018-03-01T21:42:17.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "fite",
        "biopharma",
        "ltd",
        "fite",
        "report",
        "progress",
        "phase",
        "ii",
        "nash",
        "study",
        "drug",
        "candidate",
        "namodenoson",
        "fite",
        "biopharma",
        "completion",
        "patient",
        "enrollment",
        "toward",
        "end",
        "data",
        "release",
        "first",
        "half",
        "phase",
        "ii",
        "nash",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}